|
|
Volumn 15, Issue 11, 2006, Pages 1309-1318
|
|
Discontinued drugs in 2006: Oncology drugs
|
|
Author keywords
Aprinocarsen sodium; Canvaxin ; CI 1040; Holmium 166 DOTMP; ISIS 5132; Pegamotecan; Pivaloyloxymethyl butyrate; SGN 15; Vaccine
|
|
Indexed keywords
2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE;
4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID;
6 [4 DEOXY 4 (2,4 TETRADECADIENOYLGLYCYLAMINO) GLYCERO BETA MANNOHEPTOPYRANOSYLAMINO] 9H PURINE;
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
ANTISENSE OLIGONUCLEOTIDE;
AS 1405;
BIVATUZUMAB MERTANSINE;
BIWI 1;
BLX 883;
CANCER VACCINE;
CANVAXIN;
CARBOPLATIN;
CGP 69846A;
CISPLATIN;
DISCODERMOLIDE;
F 50040;
GEMCITABINE;
GYRASE INHIBITOR;
HISTONE DEACETYLASE INHIBITOR;
ISIS 3521;
MELANOMA VACCINE;
MELPHALAN;
MONOCLONAL ANTIBODY;
PACLITAXEL;
PIVALOYLOXYMETHYL BUTYRATE;
PLACEBO;
RECOMBINANT ALPHA2B INTERFERON;
SGN 15;
TOSITUMOMAB I 131;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VORINOSTAT;
XAA 296;
NEW DRUG;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
AUTOTRANSPLANTATION;
BIOTECHNOLOGY;
BONE EROSION;
CANCER CHEMOTHERAPY;
CANCER SURGERY;
CANCER SURVIVAL;
CANCER THERAPY;
CLINICAL TRIAL;
CUTANEOUS T CELL LYMPHOMA;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG MECHANISM;
DRUG RESEARCH;
DRUG SAFETY;
DRUG STRUCTURE;
DRUG TARGETING;
EPIGENETICS;
FINANCIAL MANAGEMENT;
FUNDING;
GLIOBLASTOMA;
HEMATOLOGIC MALIGNANCY;
HUMAN;
LUNG NON SMALL CELL CANCER;
MELANOMA;
MULTIPLE MYELOMA;
SKIN TOXICITY;
STRUCTURE ACTIVITY RELATION;
SURVIVAL RATE;
SURVIVAL TIME;
UTERINE CERVIX CANCER;
TREATMENT FAILURE;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS;
DRUGS, INVESTIGATIONAL;
HUMANS;
TREATMENT FAILURE;
|
|
EID: 33750118659
PISSN: 13543784
EISSN: None
Source Type: Journal
DOI: 10.1517/13543784.15.11.1309 Document Type: Article |
|
Times cited : (36)
|
|
References (0)
|
